Publications by authors named "Adelaide Perrier"
Article Synopsis
- The study investigated the effects of the COVID-19 pandemic on the initiation and success of antiretroviral therapy (ART) for people diagnosed with HIV in the Aquitaine region of France, comparing cases from the pandemic period (2020-2021) to those diagnosed before (2018-2020).
- It involved adults diagnosed with HIV-1 and assessed key metrics such as the time from diagnosis to ART initiation and achieved viral suppression.
- Results showed that individuals diagnosed during the pandemic had a higher likelihood of starting therapy and achieving viral suppression than those diagnosed earlier, but the study noted fewer foreign-born individuals were diagnosed during the pandemic, suggesting potential barriers to care.
Background: Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage.
Methods: This large prospective cohort study of PWH examined the types of infections, bacterial documentation, and evolution of antibiotic resistance among PWH hospitalized with SBIs over an 18-year period.
Results: Between 2000 and 2017, 459 PWH had at least 1 SBI with bacterial documentation.
Article Synopsis
Article Synopsis
- Bacterial infections are a significant health issue for individuals living with HIV (PLHIV), and although statins have shown protective effects in other groups, their impact on PLHIV is still debated.
- This study aimed to assess whether statin usage reduces the chances of experiencing a first severe bacterial infection (SBI) in a large cohort of PLHIV from 2000 to 2018.
- The results indicated that statins did not significantly affect the incidence of SBIs or pneumonia among PLHIV over the 18-year follow-up period, suggesting that statins may not offer the protective benefits seen in other populations.
Background: We assessed the association of persistent low-level viraemia between 50-199 copies/ml (LLV) with the risk of virological failure (VF) among HIV-1-infected patients receiving combination antiretroviral therapy (ART).
Methods: ART-naive and ART-experienced patients followed up in the ANRS-CO3 Aquitaine Cohort were included if they started two nucleoside reverse transcriptase inhibitors (NRTIs) with either one non-nucleoside reverse transcriptase inhibitor (NNRTI) or one protease inhibitor boosted with ritonavir (PI/r) between 2000 and 2011 and achieved viral load (VL)<200 copies/ml 4-8 months after initiating ART. VF was defined as either two consecutive VL≥200 copies/ml or one VL≥200 followed by a modification of ART.